The two thrombopoietin receptor agonists (TPO-RA), eltrombopag and romiplostim, were
licensed in the US for treatment of immune thrombocytopenia (ITP) in 2008 and, since then …

The management of patients with immune thrombocytopenia (ITP) is rapidly evolving. Over
the last 15 years, a number of novel treatments have improved practice, with many steroid …

Abstract In phase 2/3 trials, eltrombopag treatment of 6 months or less in patients with
chronic/persistent immune thrombocytopenia (ITP) increased platelet counts and reduced …

Background The oral thrombopoietin receptor agonist eltrombopag is approved for treatment
of adults with chronic immune thrombocytopenia. In the PETIT trial, we aimed to investigate …

Multiple myeloma (MM) is a malignancy of plasma cells that is typically chronic, and relapse
is common. Current therapeutic strategies include combination and sequential treatments …

Background Immune thrombocytopenia (ITP) is a heterogeneous acquired disorder
characterized by isolated thrombocytopenia whose exact pathogenesis is not yet clear …

A safety analysis of pooled data from clinical studies of romiplostim, a thrombopoietin (TPO)
receptor agonist, in which patients with immune thrombocytopaenia (ITP) received …

Although understanding of the pathogenesis and molecular biology of primary myelofibrosis
continues to improve, treatment options are limited, and several biological features remain …

Prolonged thrombocytopenia after hematopoietic stem cell transplantation (HSCT) is a
strong risk factor for transplantation-related morbidity and mortality, and no standard …

Approximately 80% of adult patients with immune thrombocytopenia (ITP) have treatment
failure with corticosteroids or become dependent on them and require second-line therapy …